Drug Trial Radar · NCT02680574
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,725
Actual
Start
Feb 2016
Primary completion
Jun 18, 2020
Study completion Jul 31, 2020
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Conditions
- Anemia
- Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
VadadustatDrug
Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Darbepoetin alfaDrug
Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)Time frame: Baseline; Weeks 24 to 36
- Median Time to First Major Adverse Cardiovascular Event (MACE)Time frame: Up to Week 208
Locations
503 sites in 30 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Tuscumbia, Alabama
Research Site
Glendale, Arizona
Research Site
Mesa, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Anaheim, California
Research Site
Bakersfield, California
Research Site #1
Chula Vista, California
Research Site #2
Chula Vista, California
Research Site
El Centro, California
Research Site
Fountain Valley, California
Research Site
Glendale, California
Research Site
Granada Hills, California
Research Site
La Mesa, California
Research Site
Laguna Hills, California
Research Site
Long Beach, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Lynwood, California
Research Site #1
Northridge, California
Research Site #2
Northridge, California
Research Site
Riverside, California
Research Site
Roseville, California
Research Site
Salinas, California
Research Site
San Diego, California
Research Site #1
San Dimas, California
Research Site #2
San Dimas, California
Research Site
Santa Ana, California
Research Site
Santa Monica, California
Research Site
Sherman Oaks, California
Research Site
Thousand Oaks, California
Research Site
Whittier, California
Research Site
Whittier, California
Research Site
Arvada, Colorado
Research Site
Denver, Colorado
Research Site
Westminster, Colorado
Research Site
Stamford, Connecticut
Showing 40 of 503 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.